Clinical Applications of Dexamethasone for Aged Eyes

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drugs & Aging

• Publication date

  2016-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40266-016-0392-zPMID 27566619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Postsurgical Cystoid Macular Edema.

  2017cited by this paper
• Dexamethasone Intravitreal Implant for Diabetic Macular Edema During Pregnancy.

  2016cited by this paper
• Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

  2016cited by this paper
• Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

  2015cited by this paper
• Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular Edema

  2015cited by this paper
• Dexamethasone nanowafer as an effective therapy for dry eye disease.

  2015cited by this paper
• Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

  2015cited by this paper
• Twelve-Month Results of a Single or Multiple Dexamethasone Intravitreal Implant for Macular Edema following Uncomplicated Phacoemulsification

  2015cited by this paper
• Topical dexamethasone γ‐cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

  2015cited by this paper
• Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward

  2015cited by this paper
• Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

  2014cited by this paper
• Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab

  2014cited by this paper
• Aging: A Predisposition to Dry Eyes

  2014cited by this paper
• Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

  2014cited by this paper
• Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

  2014cited by this paper
• Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.

  2014cited by this paper
• Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

  2013cited by this paper
• Age-related psychophysical changes and low vision.

  2013cited by this paper
• Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?

  2013cited by this paper
• Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome.

  2013cited by this paper
• Pseudophakic cystoid macular edema

  2012cited by this paper
• Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

  2012cited by this paper
• Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

  2011cited by this paper
• Dexamethasone intravitreal implant for the treatment of noninfectious uveitis

  2011cited by this paper
• Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema.

  2011cited by this paper
• Postsurgical Cystoid Macular Edema

  2011cited by this paper
• Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial

  2011cited by this paper
• Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

  2011cited by this paper
• Tear osmolarity in the diagnosis and management of dry eye disease.

  2011cited by this paper
• Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

  2011cited by this paper
• Risk factors for steroid response among cataract patients

  2011cited by this paper
• The blood-retinal barrier: structure and functional significance.

  2011cited by this paper
• Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.

  2011cited by this paper
• DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS

  2011cited by this paper
• The global burden of cataract

  2011cited by this paper
• Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

  2010cited by this paper
• Targeting the Pathophysiology of Diabetic Macular Edema

  2010cited by this paper
• Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.

  2010cited by this paper
• Postsurgical cystoid macular edema.

  2010cited by this paper
• Hyperosmolarity of the tear film in dry eye syndrome.

  2010cited by this paper
• Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

  2010cited by this paper
• Molecular pathology of age-related macular degeneration.

  2009cited by this paper
• EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMA

  2009cited by this paper
• Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

  2009cited by this paper
• Intravitreal steroids for macular edema: the past, the present, and the future.

  2008cited by this paper
• Effects of Loteprednol/Tobramycin Versus Dexamethasone/Tobramycin on Intraocular Pressure in Healthy Volunteers

  2008cited by this paper
• A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

  2008cited by this paper
• Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration

  2007cited by this paper
• TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone

  2007cited by this paper
• Clinical pseudophakic cystoid macular edema: Risk factors for development and duration after treatment

  2007cited by this paper
• Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.

  2007cited by this paper
• Pathophysiology of diabetic macular edema.

  2007cited by this paper
• Corticosteroids as antiangiogenic agents.

  2006cited by this paper
• The burden of age-related macular degeneration: a value-based analysis

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.

  2006cited by this paper
• Comparison of topical 0.7% dexamethasone–cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation

  2006cited by this paper
• Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.

  2005cited by this paper
• COMBINED PHOTODYNAMIC THERAPY AND INTRAVITREAL TRIAMCINOLONE FOR NONSUBFOVEAL CHOROIDAL NEOVASCULARIZATION

  2005cited by this paper
• The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells.

  2003cited by this paper
• Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.

  2002cited by this paper
• Control of intra-ocular inflammation associated with cataract surgery

  2001cited by this paper
• Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.

  1996cited by this paper
• Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids.

  1996cited by this paper
• Identification of High Intraocular Pressure Responders to Topical Ophthalmic Corticosteroids

  1993cited by this paper
• Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

  1992cited by this paper
• Comparative study of the intraocular pressure effects of fluorometholone 0.1% versus dexamethasone 0.1%.

  1983cited by this paper
• Anti-inflammatory effectiveness of topically administered corticosteroids in the cornea without epithelium.

  1975cited by this paper

• Unveiling ferroptosis genes and inhibitors in diabetic retinopathy through single-cell analysis and docking simulations

  2025cites this paper
• Mucoadhesive Tannic Acid-Cross-Linked Nanogels for Reactive Oxygen Species Scavenging and Enhanced Ocular Therapeutic Delivery.

  2025cites this paper
• Intravitreal Sustained Release of Dexamethasone from a Self-Healing Injectable Hydrogel: An In Vivo Safety and Release Study

  2025cites this paper
• Glaucoma in general population and steroid users

  2024cites this paper
• Prescription glucocorticoid medication and iridocyclitis are associated with an increased risk of senile cataract occurrence: a Mendelian randomization study

  2024cites this paper
• Comparative Efficacy and Safety of Topical Cyclosporine, Dexamethasone and Loteprednol in Vernal Keratoconjunctivitis

  2024cites this paper
• Nanotechnological approaches to improve corticosteroids ocular therapy.

  2024cites this paper
• Development and characterization of dexamethasone nanodispersion for the effective treatment of diabetic retinopathy

  2024cites this paper
• Glaucoma Inducido por Esteroides

  2024cites this paper
• Inflammation mechanism and anti-inflammatory therapy of dry eye

  2024cites this paper
• Improving corneal permeability of dexamethasone using penetration enhancing agents: First step towards achieving topical drug delivery to the retina.

  2024cites this paper
• Childhood Uveitic Glaucoma: Complex Management in a Fragile Population

  2023cites this paper
• Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

  2022cites this paper
• Self-Healing Thermosensitive Hydrogel for Sustained Release of Dexamethasone for Ocular Therapy

  2022cites this paper
• Pharmacokinetics of Pullulan–Dexamethasone Conjugates in Retinal Drug Delivery

  2021cites this paper
• A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery

  2021cites this paper
• CORTICOSTEROID- TRIAL STATUS, BENEFITS AND PITFALLS OF DEXAMETHASONE IN SITUATION OF COVID-19 PANDEMIC

  2020cites this paper
• Characterization of Zinc Oxide Nanoparticle Cross-Linked Collagen Hydrogels

  2020cites this paper
• Steroid Induced Glaucoma: epidemiology, pathophysiology and clinical management.

  2020cites this paper
• Effects of preoperative doses of betamethasone acetate 0.1% on dry eye control after cataract surgery

  2020cites this paper
• Dropless cataract surgery: modernizing perioperative medical therapy to improve outcomes and patient satisfaction.

  2020cites this paper
• Release of functional dexamethasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery.

  2020cites this paper
• Results from the Population-Based Gutenberg Health Study Revealing Four Altered Autoantibodies in Retinal Vein Occlusion Patients

  2020cites this paper
• Manufacturing of Dexamethasone–Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons

  2020cites this paper
• Punctum and canalicular anatomy for hydrogel-based intracanalicular insert technology.

  2020cites this paper
• Mitochondrial Dynamics Impairment in Dexamethasone-Treated Neuronal Cells

  2019cites this paper
• Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy

  2018cites this paper
• Cyclodextrin-containing hydrogels as an intraocular lens for sustained drug release

  2017cites this paper
• Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit

  2017cites this paper
• Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New Dexamethasone Delivery System for Inflammatory Diseases

  2017cites this paper
• Steroid Induced Glaucoma

  2011cites this paper